3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors
Shelley Allen, Niwot, CO (US); Patrick Michael Doerner Barbour, Westminster, CO (US); James Francis Blake, Longmont, CO (US); Sydney Taylor Blanche, Longmont, CO (US); Mark Laurence Boys, Lyons, CO (US); Wesley Dewitt Clark, Gales Ferry, CT (US); Connor James Cowdrey, Longmont, CO (US); Joshua Ryan Dahlke, Longmont, CO (US); Alex Andrew Kellum, Boulder, CO (US); Ellen Margaret Knapp, Lafayette, CO (US); David Austin Moreno, Centennial, CO (US); Jacob Matthew O'Leary, Boston, MA (US); Li Ren, Superior, CO (US); Faith Elizabeth Witkos, Attleboro, MA (US); and Jennifer Lynn Fulton, Longmont, CO (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Dec. 1, 2022, as Appl. No. 18/60,864.
Application 18/060,864 is a continuation of application No. 17/708,072, filed on Mar. 30, 2022.
Claims priority of provisional application 63/309,346, filed on Feb. 11, 2022.
Claims priority of provisional application 63/168,456, filed on Mar. 31, 2021.
Prior Publication US 2023/0120188 A1, Apr. 20, 2023
